INTRODUCTION
The p21ras protooncogenes are a heterologous family of GTP/GDP-binding, growth promoting proteins located downstream of receptor associated TK's in many cell types. The activity of these proteins is regulated by their bound GTP/GDP ratio and is directly proportional to this ratio; GTP-p21ras and GDP-p21ras are the active and the non-active states, respectively. The relative amounts of GTP and GDP bound to p21ras are regulated by two opposing factors. 
p21ras
- [3] Insulin resistance plays a major role in the pathogenesis and progression of Type II Diabetes. Its cause is unknown in the vast majority of patients and is commonly attributed to post insulin receptor signaling defect. [41 Insulin receptor signaling is mediated in part via the p21ras pathway. [5] [6] [7] Over-expression of a p21ras like protein called "ras associated with diabetes" (RAD) has been reported in muscle tissue of patients with type II diabetes and implicated as a cause of insulin resistance in these patients. [8] However, genetic studies failed to confirm a linkage between the rad locus and familial predisposition to type II diabetes. [9] Furthermore, we previously reported that the induced activity, as well as expression of p21ras and its regulatory factors were normal in PBMC of insulin treated type II patients and comparable to non-diabetic control patients. [1] In this work, we examined for the first time the function and expression of the p21ras pathway in a subset of these patients characterized by high insulin requirements and poor metabolic control to further determine the role of p21ras pathway in mediating the insulin resistance in type II diabetes. Determination of MAP-kinase activity was [13] performed as previously described. We previously reported a normal p21ras pathway expression in the presence of defective lymphocyte activation and proliferation. [14] Therefore, we determined the mitogen mediated in vitro proliferation of our insulin resistant and wellcontrolled patients. The mean proliferative response to PHA was comparable in insulin resistant and well-controlled patients: SI of 16.4 + 8.6 and 14.5_ 7.8, respectively (Fig. 4) We previously demonstrated that reduced activation of the p21ras pathway is detectable in the presence of normal expression of p21ras and its regulatory factors. [1, 14, 151 In addition, a variety of signaling defects has been reported in PBMC from type II patients [16-18I and hyperglycemia has been implicated as a reversible cause of aberrant T cell activation in diabetic patients. [19] [21, 221 and by the recent demonstration that ras transformed brown adipocytes developed insulin resistance due to a signaling defect up-stream of ras, without decreasing the activity of p21ras down-stream elements. [23] It is also supported by our previous demonstration in type I patients and pre-diabetic animals of a restricted defect in the activation of p21ras located up-stream of PKC p21ras complex and the cell membrane. [1,14A5] 
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